Welcome to our dedicated page for United States Antimony SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The United States Antimony Corporation (UAMY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. UAMY’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the NYSE American and NYSE Texas, so investors can review a range of filings, including Form 8-K current reports that detail material events and corporate developments.
Recent Form 8-K filings for United States Antimony cover topics such as entry into material definitive agreements, including a five-year supply agreement with a U.S. industrial fabric manufacturer for antimony trioxide, and capital markets transactions under shelf registration statements and sales agreements. Other 8-Ks report on operational updates, preliminary revenue guidance, and proposals related to potential acquisitions, as well as the appointment of new independent directors and the formation of board committees.
Filings also disclose information about conference calls and press releases reporting financial and operational results for periods such as the third quarter and nine months ended September 30, 2025. These documents outline revenues, gross profit, operating expenses, net loss, and balance sheet data, along with narrative discussion of antimony and zeolite sales and capital expenditures for smelter expansion and mineral rights purchases.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that help explain the significance of each filing. Investors can quickly scan Form 8-K disclosures for key points on contracts, financing, governance changes, and operational guidance, and then dive into the full text when more detail is needed. For those tracking UAMY’s role in antimony, zeolite, and critical minerals, these filings provide an official record of the company’s regulatory and financial reporting.
United States Antimony Corp (UAMY) director and officer Lloyd Bardswich reported a sale of 40,000 shares of the company's common stock on 09/29/2025 at a price of $6.44 per share. After the sale the filing shows beneficial ownership listed as 594.047 (as reported). The Form 4 was signed by the reporting person on 10/04/2025. No derivative transactions or additional purchases were disclosed.
Jeffrey Russell Fink, an officer and director of United States Antimony Corp (UAMY), reported two open-market dispositions on 10/03/2025. The filing shows a sale of 2,833 shares at $8.16 and a sale of 8,000 shares at $8.12. After those transactions the reported beneficial ownership totals are listed as 64,000 shares and 56,000, respectively, held in a direct capacity. The Form 4 is signed by the reporting person and indicates the transactions were not reported as part of a 10b5-1 plan. The filing provides a straightforward record of insider selling activity without additional commentary or explanatory notes.
UAMY filed a Form 144 notice for proposed sales of common stock.
The notice lists 2,833 shares (aggregate market value $23,103.12) and 8,000 shares (aggregate market value $64,960.80) to be sold through Merrill Edge on NYSE American, with an approximate sale date of October 3, 2025. The seller acquired 33,333 shares via restricted stock vesting on January 29, 2025 as compensation.
United States Antimony Corp (UAMY) director Michael A. McManus Jr. reported selling 50,000 shares of common stock on 10/01/2025 at a reported price of $7.316 per share. After the sale he beneficially owns 531,965 shares. The Form 4 was signed on 10/02/2025 and shows the transaction as a direct disposition by a director.
United States Antimony Corp (UAMY) filed a Form 144 disclosing a proposed sale of 50,000 common shares with an aggregate market value of $350,000. The filing states the shares represent part of the company's outstanding 120,723,320 shares and that the approximate sale date is 10/01/2025 through the NYSE via Merrill Lynch. The shares were acquired on 05/15/2024 as a stock bonus from US Antimony Corp, and no sales by the same person were reported in the past three months. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.
United States Antimony Corp (UAMY) filed a Form 144 reporting a proposed sale of 12,500 common shares through Merrill EDGE (Jacksonville, FL) on the NYSE American with an approximate aggregate market value of $98,375. The shares were acquired on 01/29/2025 as restricted stock vesting from the issuer, totaling 33,333 shares received on that date and paid as compensation. The filer reports 120,723,320 shares outstanding and lists an approximate sale date of 09/24/2025. The filing states there were no securities sold in the past three months by the selling person and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for United States Antimony Corp (UAMY) reporting a proposed sale of 40,000 common shares with an aggregate market value of $245,000, listed for an approximate sale date of 09/29/2025 on NYSE American through broker Canaccord Genuity.
The filing shows the shares were originally acquired in open-market cash purchases on 08/18/2022 and 08/19/2022 in four lots totaling the 40,000 shares, with payment settled in cash. The issuer has 120,723,320 shares outstanding. The filer reports no sales of these securities in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Jeffrey R. Fink, an officer and director of United States Antimony Corp (UAMY), reported the sale of 12,500 shares of the company's common stock on September 24, 2025 at a reported price of $7.87 per share. After the transaction he beneficially owned 66,833 shares. The Form 4 was signed on October 2, 2025. The filing discloses a straightforward open-market disposition by an insider and contains no derivative transactions or additional explanations.
Richard R. Isaak, Senior Vice President and Chief Financial Officer of United States Antimony Corp (UAMY), reported a sale of 50,000 shares of the company's common stock on 10/01/2025 at a price of $7 per share. Following the reported disposition, he beneficially owns 251,744 shares. The Form 4 was signed by Mr. Isaak on 10/01/2025.
Form 144 filing for UNITED STATES ANTIMONY CORP (UAMY) reports a proposed sale of 50,000 common shares through Merrill Lynch in New York with an aggregate market value of $365,791.80 and an approximate sale date of 10/01/2025. The filer reports acquiring 135,000 of the shares on 08/14/2024 in an open market purchase paid in cash. The issuer has 128,727,843 shares outstanding as stated. The notice includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer.